|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2003-4-2
|
|
pubmed:abstractText |
This open-label, prospective study was conducted to compare the impact of epoetin beta vs standard care on quality of life (QoL) in anaemic patients with lymphoid or solid tumour malignancies. A total of 262 anaemic patients (haemoglobin [Hb]<or=11 g dl(-1)) were randomised to a 12-week treatment with s.c. epoetin beta (initial dose 150 IU kg(-1) three times weekly) or standard care. Transfusions were recommended for both groups at an Hb threshold of 8.5 g dl(-1). The primary efficacy variables were improvement in QoL as measured using the Short-Form-36 physical component summary (SF-36 PCS) score and the Functional Assessment of Cancer Therapy fatigue and anaemia subscales (FACT-F and FACT-An). A visual analogue scale (VAS) was also used as a global QoL measure. Clinical response was defined as a >or=2 g dl(-1) increase in Hb level without need of transfusion after the initial 4 weeks of treatment. Baseline to final visit changes in SF-36 PCS, FACT-F and VAS scores were significantly greater with epoetin beta than with standard care (P<0.05); changes in FACT-An subscale score tended to be greater with epoetin beta (P=0.076). Epoetin beta significantly increased Hb concentrations relative to standard care (responders: 47% vs 13%; P<0.001). Levels of endogenous erythropoietin <50 mIU ml(-1) were significantly predictive of response (OR 2.496, 95% CI: 1.21-5.13). Epoetin beta therapy significantly improves QoL compared with standard care in anaemic patients with solid tumours and lymphoid malignancies.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-10334673,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-10511589,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-10526282,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-10662393,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-11040270,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-11328297,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-11387359,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-11387360,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-11413508,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-12011126,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-1353804,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-1482651,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-1581207,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-7723455,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-7738630,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-7772519,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-7896210,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-8164030,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-8424398,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-8487324,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-8541533,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-8639883,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-8952157,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-8997459,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-9060566,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-9095563,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-9689556,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-9779721,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-9785333,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-9819794,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-9834824,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12671693-9879342
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
7
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
988-95
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12671693-Adult,
pubmed-meshheading:12671693-Aged,
pubmed-meshheading:12671693-Aged, 80 and over,
pubmed-meshheading:12671693-Erythropoietin,
pubmed-meshheading:12671693-Female,
pubmed-meshheading:12671693-Humans,
pubmed-meshheading:12671693-Male,
pubmed-meshheading:12671693-Middle Aged,
pubmed-meshheading:12671693-Neoplasms,
pubmed-meshheading:12671693-Prospective Studies,
pubmed-meshheading:12671693-Quality of Life,
pubmed-meshheading:12671693-Recombinant Proteins
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Impact of epoetin beta on quality of life in patients with malignant disease.
|
|
pubmed:affiliation |
Labo Hematologie Transplant, U.Z. Gasthuisberg, Leuven, Belgium. Marc.Boogaerts@med.kuleuven.ac.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
